<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23860530</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-1827</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>109</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of cancer</Title>
                <ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>859-65</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2013.400</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We evaluated the efficacy of aprepitant plus granisetron and an increased dose of dexamethasone in selected patients undergoing moderately emetogenic chemotherapy (MEC).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Nondrinking women &lt;70 years undergoing MEC were randomly assigned to aprepitant (day 1, 125 mg; days 2 and 3, 80 mg) or placebo. Dexamethasone on days 1-3 was 12, 4, and 4 mg with aprepitant and 20, 8, and 8 mg with placebo. The primary end point was complete response (CR; no emesis or rescue therapy) during 120 h of the first cycle. Logistic regression analysis was performed to identify predictors of overall CR.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 94 patients enrolled, 91 were assessable. Most received carboplatin-based chemotherapy. In the aprepitant (n=45) and placebo (n=46) groups, the overall, acute (day 1), and delayed (days 2-5) CR rates were 62% and 52%, 98% and 96%, and 62% and 52%, respectively. Although not statistically significant, the overall CR rate was 10% higher in the aprepitant group. Both regimens were well tolerated. On multivariate analysis, advanced ovarian cancer (OR, 0.26 (0.10-0.72)) was independently associated with a lower CR.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Even with an increased dose of dexamethasone, aprepitant seemed more effective than placebo in these selected patients undergoing MEC; however, delayed phase management remains a significant problem.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tanioka</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology, Hyogo Cancer Center, Akashi, Japan. tanioka@hp.pref.hyogo.jp</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitao</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsumoto</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shibata</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamaguchi</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujiwara</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Minami</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Katakami</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morita</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Negoro</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>07</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Cancer</MedlineTA>
            <NlmUniqueID>0370635</NlmUniqueID>
            <ISSNLinking>0007-0920</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000932">Antiemetics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1NF15YR6UY</RegistryNumber>
                <NameOfSubstance UI="D000077608">Aprepitant</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7673326042</RegistryNumber>
                <NameOfSubstance UI="D000077146">Irinotecan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7S5I7G3JQL</RegistryNumber>
                <NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>BG3F62OND5</RegistryNumber>
                <NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WZG3J2MCOL</RegistryNumber>
                <NameOfSubstance UI="D017829">Granisetron</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>XT3Z54Z28A</RegistryNumber>
                <NameOfSubstance UI="D002166">Camptothecin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000932" MajorTopicYN="N">Antiemetics</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077608" MajorTopicYN="N">Aprepitant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002166" MajorTopicYN="N">Camptothecin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017829" MajorTopicYN="N">Granisetron</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077146" MajorTopicYN="N">Irinotecan</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013695" MajorTopicYN="Y">Temperance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014839" MajorTopicYN="N">Vomiting</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>03</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>06</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>06</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23860530</ArticleId>
            <ArticleId IdType="pii">bjc2013400</ArticleId>
            <ArticleId IdType="doi">10.1038/bjc.2013.400</ArticleId>
            <ArticleId IdType="pmc">PMC3749572</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Support Care Cancer. 2010 Sep;18(9):1171-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19756774</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2010 May;21 Suppl 5:v232-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20555089</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 Nov 1;29(31):4189-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21947834</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Compr Canc Netw. 2012 Apr;10(4):456-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22491046</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 Sep 20;30(27):3389-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22915657</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuroendocrinology. 2000 Apr;71(4):228-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10773742</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2000 Oct 1;18(19):3409-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11013282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Obstet Gynecol. 2003 Apr;101(4):639-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12681864</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2003 Jun 15;97(12):3090-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12784346</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Nov 15;21(22):4112-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14559886</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1986 Feb;4(2):224-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3944606</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1989 Sep 1;64(5):1117-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2667749</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Physiol. 1996 Mar;270(3 Pt 1):G506-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8638718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1997 Jan;15(1):116-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8996132</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Neurosci Res. 1997 Oct 1;50(1):94-103</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9379497</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Endocrinol. 1997 Dec 12;135(2):109-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9484906</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1998 Sep;16(9):2937-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9738561</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 Apr 20;23(12):2822-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15837996</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Clin Pract Oncol. 2005 Apr;2(4):196-201</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16264934</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2006 Mar;17 Suppl 2:ii96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16608997</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2006 Jun;17(6):1000-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16524979</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Jun 20;24(18):2932-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16717289</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Support Oncol. 2007 Feb;5(2 Suppl 1):5-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17366928</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2008 Jun 5;358(23):2482-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18525044</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Support Care Cancer. 2010 Apr;18(4):423-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19568773</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Support Oncol. 2011 Sep-Oct;9(5):188-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22024310</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>